447 related articles for article (PubMed ID: 17202317)
1. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.
Li Y; Toraldo G; Li A; Yang X; Zhang H; Qian WP; Weitzmann MN
Blood; 2007 May; 109(9):3839-48. PubMed ID: 17202317
[TBL] [Abstract][Full Text] [Related]
2. Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL.
Kassem A; Lindholm C; Lerner UH
PLoS One; 2016; 11(6):e0156708. PubMed ID: 27311019
[TBL] [Abstract][Full Text] [Related]
3. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
4. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
5. T cells potentiate PTH-induced cortical bone loss through CD40L signaling.
Gao Y; Wu X; Terauchi M; Li JY; Grassi F; Galley S; Yang X; Weitzmann MN; Pacifici R
Cell Metab; 2008 Aug; 8(2):132-45. PubMed ID: 18680714
[TBL] [Abstract][Full Text] [Related]
6. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
8. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
9. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
[TBL] [Abstract][Full Text] [Related]
10. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
11. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
12. Osteoimmunology and its implications for transplantation.
Pacifici R
Am J Transplant; 2013 Sep; 13(9):2245-54. PubMed ID: 23915249
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
14. [Bone remodeling and mineral homeostasis].
Nakamura M; Udagawa N; Nakamura H
Clin Calcium; 2006 Jan; 16(1):46-53. PubMed ID: 16397350
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
Li M; Xu D
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
[TBL] [Abstract][Full Text] [Related]
16. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
Palmqvist P; Persson E; Conaway HH; Lerner UH
J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts.
Nakamichi Y; Udagawa N; Kobayashi Y; Nakamura M; Yamamoto Y; Yamashita T; Mizoguchi T; Sato M; Mogi M; Penninger JM; Takahashi N
J Immunol; 2007 Jan; 178(1):192-200. PubMed ID: 17182555
[TBL] [Abstract][Full Text] [Related]
18. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
[TBL] [Abstract][Full Text] [Related]
19. [Osteoclastogenesis and bone resorption].
Nakamura M; Nakamichi Y; Nakamura H; Udagawa N
Nihon Rinsho; 2009 May; 67(5):889-96. PubMed ID: 19432105
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
